RxSight, Inc. (RXST)
NASDAQ: RXST · Real-Time Price · USD
5.40
-0.21 (-3.74%)
Jul 21, 2026, 1:43 PM EDT - Market open
RxSight Revenue
RxSight had revenue of $30.89M in the quarter ending March 31, 2026, a decrease of -18.48%. This brings the company's revenue in the last twelve months to $127.48M, down -14.05% year-over-year. In the year 2025, RxSight had annual revenue of $134.48M, down -3.89%.
Revenue (ttm)
$127.48M
Revenue Growth
-14.05%
P/S Ratio
1.81
Revenue / Employee
$276,523
Employees
461
Market Cap
223.54M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 134.48M | -5.45M | -3.89% |
| Dec 31, 2024 | 139.93M | 50.85M | 57.09% |
| Dec 31, 2023 | 89.08M | 40.07M | 81.77% |
| Dec 31, 2022 | 49.01M | 26.41M | 116.90% |
| Dec 31, 2021 | 22.59M | 7.92M | 53.92% |
| Dec 31, 2020 | 14.68M | 12.44M | 554.98% |
| Dec 31, 2019 | 2.24M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Treace Medical Concepts | 207.32M |
| Quanterix | 144.98M |
| InfuSystem Holdings | 142.40M |
| Sight Sciences | 79.55M |
| 908 Devices | 57.80M |
| Apyx Medical | 55.90M |
| TriSalus Life Sciences | 44.88M |
| Senseonics Holdings | 40.71M |
RXST News
- 5 days ago - RxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed - TheFly
- 5 days ago - RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer - GlobeNewsWire
- 13 days ago - Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - Business Wire
- 13 days ago - RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M - TheFly
- 13 days ago - RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M - TheFly
- 13 days ago - RxSight price target lowered to $6.50 from $7.50 at Jefferies - TheFly
- 13 days ago - The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - Business Wire
- 14 days ago - RxSight price target lowered to $6.50 from $8 at BofA - TheFly